MediPharm Labs Enters Denmark Healthcare Cannabis Marketplace, Secures New White-Label Provide Clients

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a worldwide leader in specialized, study-driven pharmaceutical-top quality cannabis extraction, distillation and derivative items, now announced it will provide cannabis concentrate items in Denmark to two new health-related cannabis prospects beneath two separate white-label agreements. These prospects will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ very first provide agreements for the export of completed items to Denmark.

Denmark granted sufferers legal access to cannabis-primarily based medicinal items two years ago as aspect of a 4-year pilot plan. The plan delivers sufferers with protected solution access and national wellness authorities with patient information that they can use to recognize usage and efficacy. According to data complied by New Frontier Information and the Danish Ministry of Overall health, more than two,one hundred sufferers (mainly ladies among the ages of 42-64) received cannabis-primarily based medicinal items from 429 prescribing physicians beneath this plan in 2019.

“The express goal of establishing a multi-jurisdictional, GMP-certified production capability is to lead the worldwide cannabis marketplace for medicinal, wellness and adult use applications and these agreements represent an additional step forward in realizing our ambitions,” stated Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish health-related marketplace with new and revolutionary health-related cannabis focused items positions us for added development in Europe and adds to MediPharm Labs all-crucial physique of understanding that we are leveraging to boost the style of our formulations for sufferers and shoppers everywhere.”

Below the agreements, one particular which has an initial two-year term and the second a one particular-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil items that will be white-labeled for distribution.

MediPharm Labs anticipates delivery to its prospects to commence in October 2020, pending regulatory approval by applicable wellness authorities.

GMP Certification Ignites Development for MediPharm Labs Australia

“Since the starting of 2020, MediPharm Labs Australia has secured various incredibly eye-catching domestic and international provide agreements with higher top quality partners, now such as new prospects in Denmark,” stated Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new organization wins are a clear and crucial validation of our selection to make a GMP certified cannabis extraction facility provide chain for planet markets and a testament to MediPharm Labs increasing profile and reputation. We appear forward to ramping up production beneath all of these agreements.”

MediPharm Labs Australia received its Very good Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in May perhaps 2020, which enables it to sell cannabis APIs and completed items to nations across the EU, such as Denmark. The Organization entered into its very first European white-label cannabis provide agreement that similar month with Therismos Restricted.

About Denmark’s Healthcare Cannabis Marketplace

Denmark launched its 4-year health-related cannabis pilot plan on January 1st, 20181. Post-harvest Very good Manufacturing Processes (GMP) is needed for distribution of health-related cannabis items in Denmarktwo.

Via the plan, physicians can prescribe health-related cannabis for all purposes and are guided by suggestions in 4 regions: discomfort brought on by a number of sclerosis, discomfort brought on by spinal cord harm, side effects from chemotherapy therapy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The recommendations published by the Danish Medicines Agency are primarily based on an in depth critique of literature as nicely as assessments of: cannabis schemes in the Netherlands, Canada and Israel earlier cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical top quality cannabis oil and concentrates and sophisticated derivative items using a Very good Manufacturing Practices certified facility with ISO typical constructed clean rooms. MediPharm Labs has invested in an specialist, study-driven group, state-of-the-art technologies, downstream purification methodologies and goal-constructed facilities with 5 principal extraction lines for delivery of pure, trusted and precision -dosed cannabis items for its prospects. Via its wholesale and white label platforms, they formulate, customer-test, course of action, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based items to domestic and international markets. As a worldwide leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.

For additional data, please get in touch with:
Laura Lepore, VP, Investor Relations
Phone: 705-719-7425 ext 1525
E mail: [email protected]
Web page: www.medipharmlabs.com

______________________________
1 Medicinal Cannabis Pilot System. Retrieved: https://laegemiddelstyrelsen.dk/en/specific/medicinal-cannabis/citizens/medicinal-cannabis-pilot-programme/
two The Healthcare Cannabis Marketplace in Denmark &amp Europe. Retrieved: https://www.openaccessgovernment.org/the-health-related-cannabis-marketplace-in-denmark-europe/80721/
three The Danish Healthcare Cannabis Pilot Programme: Placing the Patient Very first. Retrieved: https://www.healtheuropa.eu/the-danish-health-related-cannabis-pilot-programme-placing-the-patient-very first/92991/

CAUTIONARY NOTE With regards to FORWARD-Seeking Data:

This news release includes “forward-seeking information” and “forward-seeking statements” (collectively, “forward-seeking statements”) inside the which means of the applicable Canadian securities legislation. All statements, other than statements of historical truth, are forward-seeking statements and are primarily based on expectations, estimates and projections as at the date of this news release. Any statement that entails discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or overall performance (usually but not often applying phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that specific actions, events or final results “may” or “could”, “would”, “might” or “will” be taken to take place or be accomplished) are not statements of historical truth and might be forward-seeking statements. In this news release, forward-seeking statements relate to, amongst other factors, the thriving overall performance of the agreements and shipping of items thereunder as planned added development in Europe and enhancing the style of formulations. Forward-seeking statements are necessarily primarily based upon a quantity of estimates and assumptions that, though regarded as affordable, are topic to identified and unknown dangers, uncertainties, and other variables which might lead to the actual final results and future events to differ materially from these expressed or implied by such forward-seeking statements. Such variables include things like, but are not restricted to: common organization, financial, competitive, political and social uncertainties the inability of MediPharm Labs to acquire sufficient financing the delay or failure to obtain regulatory approvals and other variables discussed in MediPharm Labs’ filings, out there on the SEDAR site at www.sedar.com. There can be no assurance that such statements will prove to be precise, as actual final results and future events could differ materially from these anticipated in such statements. Accordingly, readers need to not spot undue reliance on the forward-seeking statements and data contained in this news release. Except as needed by law, MediPharm Labs assumes no obligation to update the forward-seeking statements of beliefs, opinions, projections, or other variables, need to they transform.

Latest posts